Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Innovation Pharmaceuticals announces CTA for COVID-19 clinical study » 09:18
11/16/20
11/16
09:18
11/16/20
09:18
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals announces that an overseas Clinical Trial Application has been submitted to the governing health agency, with a U.S. Investigational New Drug application also to be submitted this week to the FDA. Both these submissions are part of final preparations for the Company's multinational Phase 2 clinical trial of Brilacidin for COVID-19, which is on track to commence in 2020 upon gaining required approvals. The randomized, double-blind, placebo-controlled, multi-center study is anticipated to enroll 120 hospitalized patients with COVID-19. Sufficient Brilacidin intravenous drug product has been manufactured to complete this trial, and potentially future COVID-19 trials, providing the Company with added flexibility as it develops Brilacidin for the treatment of COVID-19. In other important news, the Company has been informed by researchers at George Mason University's Regional Biocontainment Laboratory that new in vitro testing showed Brilacidin exerted similarly potent inhibition against two strains of SARS-CoV-2, the novel coronavirus responsible for COVID-19. These data suggest Brilacidin would likely not be susceptible to resistance developing due to SARS-CoV-2 mutations, unlike many other vaccines and antivirals currently in use and in development.

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Hot Stocks
Innovation Pharmaceuticals receives pre-IND response from FDA on COVID-19 trial » 09:31
11/02/20
11/02
09:31
11/02/20
09:31
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals announced receipt of written feedback from the U.S. Food and Drug Administration that is in general agreement with the Company's planned clinical trial for Brilacidin, a defensin-mimetic drug candidate, for the treatment of COVID-19. The FDA response completes the Pre-Investigational New Drug process. The FDA provided feedback on clinical development plans for the evaluation of Brilacidin as a treatment for COVID-19. The Company is now incorporating this feedback and finalizing the trial protocol for its planned Phase 2, randomized, double-blind, placebo-controlled, multi-national study to evaluate the efficacy and safety of Brilacidin in hospitalized patients with COVID-19. Target enrollment for the trial is 120 patients. Contract Research Organizations have been secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study. The Company anticipates commencing the Brilacidin for COVID-19 clinical trial in 4Q2020.

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Hot Stocks
Innovation, George Mason University complete brilacidin lab testing » 07:36
10/30/20
10/30
07:36
10/30/20
07:36
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals and George Mason University's National Center for Biodefense and Infectious Diseases jointly announce completion of extensive laboratory testing supporting anti-SARS-CoV-2 activity of Brilacidin, a defensin-mimetic drug candidate, which is being developed as a potential COVID-19 treatment. Preprint article details research conducted at George Mason's Regional Biocontainment Laboratory: Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing COVID-19. In a human lung cell line infected by SARS-CoV-2, Brilacidin achieved a high Selectivity Index of 426. The primary mechanism of action of Brilacidin appears to disrupt viral integrity and block viral entry. Brilacidin and FDA-approved remdesivir exhibit excellent synergistic activity in vitro against SARS-CoV-2. "During the global COVID-19 pandemic, we selectively formed new external industry partnerships, including this opportunity to research a drug candidate like Brilacidin," said Aarthi Narayanan, PhD, Associate Professor of Systems Biology in Mason's College of Science. "In testing at GMU's BSL-3 lab, we showed that Brilacidin potently inhibits SARS-CoV-2 in vitro against the live virus. Beyond exhibiting treatment potential for those already infected by COVID-19, Brilacidin's ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic. I look forward to working with Innovation to investigate further Brilacidin's antiviral properties."

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Over a month ago
Hot Stocks
Innovation Pharmaceuticals reports data from ongoing lab testing of brilacidin » 09:14
09/15/20
09/15
09:14
09/15/20
09:14
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals reports receiving additional data from a U.S. Regional Biocontainment Laboratory collected during ongoing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19. In human lung epithelial cell line experiments performed at the RBL, Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels. Brilacidin appears to have primarily an extracellular mechanism of action, by disrupting viral integrity and blocking viral entry. In contrast, Remdesivir-currently authorized by the FDA for emergency use against COVID-19-has an intracellular mechanism of action, affecting viral replication post-infection. Exhibiting different but synergistic antiviral properties, these two drugs may be an especially potent drug combination in treating COVID-19. In other newly conducted lab testing at the RBL, Brilacidin was shown to inhibit SARS-CoV-2 in a human intestinal epithelial cell line and in primary fibroblast cells obtained from human donors. The Company has been informed by the RBL that it is nearing completion of its in vitro testing of Brilacidin against SARS-CoV-2 and will be submitting findings for peer-review publication. The publication will be solely focused on Brilacidin, with a pre-print made available.

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Over a quarter ago
Hot Stocks
Innovation Pharmaceuticals, U.S. RBL nearing completion of brilacidin testing » 09:01
08/04/20
08/04
09:01
08/04/20
09:01
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals reports receiving an update from a U.S. Regional Biocontainment Laboratory based on ongoing in vitro testing supporting Brilacidin as a treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19. A new experiment in a human lung epithelial cell line with the live virus showed that Brilacidin inhibited SARS-CoV-2 when administered post-infection. These results complement earlier RBL experiments in the same lung cell line that showed Brilacidin, when directly incubated with the live virus, exhibited potent inhibition. As Brilacidin is showing consistent and robust anti-SARS-CoV-2 activity across the viral lifecycle, the Company believes the drug could be used as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected. At the RBL, ongoing direct inhibition experiments are being conducted with the live virus, including experiments to determine the Selectivity Index-a ratio that compares a drug's cytotoxicity and antiviral activity-of Brilacidin in human lung cells and also in Vero cells. New in vitro neutralization experiments and binding experiments are helping to further elucidate Brilacidin's antiviral mechanisms against SARS-CoV-2. The richness of the growing RBL data is informing our planned Phase 2 clinical trial of Brilacidin for COVID-19. Upon completion of in vitro testing at the RBL, an academic paper is anticipated to be submitted in September for peer-review publication, with a pre-print to be made available at that time.

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Hot Stocks
Innovation Pharmaceuticals grants licensing rights to FCCDC » 08:24
07/22/20
07/22
08:24
07/22/20
08:24
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals announced that the Company and Fox Chase Chemical Diversity Center have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six percent fee tied to all potential future proceeds-including upfront payments, milestone payments and royalties-the Company is granting FCCDC all discovery, intellectual property and commercialization rights related to its share of their joint antifungal drug program. Both parties believe the new agreement is favorable to each, with FCCDC continuing to advance discovery and drug development, and Innovation Pharmaceuticals benefiting from potential future commercialization. Over $5M in government grants have helped fund antifungal work conducted to date.

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Hot Stocks
Innovation Pharmaceuticals reports data from ongoing lab testing of brilacidin » 07:40
07/20/20
07/20
07:40
07/20/20
07:40
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals reports receiving new data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory. The data is helping to inform the planned Phase 2 clinical trial of Brilacidin for COVID-19, targeted to commence in Q4 2020. Recently released in vitro data showed Brilacidin exhibited a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human lung epithelial cell line-reducing viral load by 95 percent and 97 percent at two efficacious concentrations tested, compared to control. The new data, using the same assay method, reveal Brilacidin exhibited a similarly potent inhibitory effect against SARS-CoV-2 at an even lower concentration in the same human lung epithelial cell line. Brilacidin achieved approximately 90 percent inhibition of SARS-CoV-2 at a drug concentration that was one-half lower than previously tested. The lowest concentration of Brilacidin used in RBL testing to date is well below the clinically-achievable concentration based on the pharmacokinetics observed in the Company's Phase 2b clinical trial of Brilacidin in Acute Bacterial Skin and Skin Structure Infections. Additional RBL testing will assess Brilacidin's inhibition against SARS-CoV-2 in the human lung epithelial cell line at even lower concentrations to allow for accurate determination of Brilacidin IC50 and IC90 values-the drug concentration at which 50 percent and 90 percent of the virus is inhibited. IC90 rather than IC50 values are considered valuable measures of drug potency as they are more likely to reflect in vitro results translating to comparable results in humans.

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Hot Stocks
Innovation Pharmaceuticals to start clinical trial testing of brilacidin in Q4 » 08:13
07/13/20
07/13
08:13
07/13/20
08:13
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals provides perspectives on the planned clinical trial testing of Brilacidin, administered intravenously, for the treatment of COVID-19. The exigencies of the pandemic coupled with Brilacidin's multiple therapeutic properties - its anti-viral SARS-CoV-2 activity, its anti-inflammatory potential to abate the COVID-19 associated cytokine storm, as well as its proven anti-bacterial properties - have the Company working vigilantly to advance Brilacidin into human trials against COVID-19 during fourth-quarter 2020. As previously released, manufacturing steps are now underway to prepare Brilacidin for COVID-19 clinical trial use, including the sourcing of materials and making of sterile IV drug product. In parallel to these manufacturing efforts, the Company has drafted a study protocol toward initiating a planned Phase 2 trial of Brilacidin for COVID-19. This proposed study has two active treatment arms evaluating different IV dosing regimens in hospitalized patients with COVID-19. The ongoing in vitro testing at independent laboratories of Brilacidin against SARS-CoV-2, in which Brilacidin has shown consistently robust results in human and animal cell lines, is helping to inform trial design. Given the continuing coronavirus pandemic, and especially in light of surging cases in the United States, the Company is looking to start a clinical trial with Brilacidin for COVID-19 treatment in Q4 2020. This forecast assumes manufacturing is completed, per the manufacturer's timeline, and a successful nvestigational New Drug application with the Food and Drug Administration.

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Syndicate
Innovation Pharmaceuticals files $60M mixed securities shelf  17:15
07/10/20
07/10
17:15
07/10/20
17:15
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Hot Stocks
Innovation Pharmaceuticals reports data from ongoing lab testing of brilacidin » 07:40
06/17/20
06/17
07:40
06/17/20
07:40
IPIX

Innovation Pharmaceuticals

$0.00 /

+ (+0.00%)

Innovation…

Innovation Pharmaceuticals reports receiving data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory. Brilacidin exhibited a statistically significant and potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human lung epithelial cell line-reducing viral load by 95 percent and by 97 percent, compared to control, at two therapeutic concentrations tested. Based on a CC50 value-the concentration of drug at which 50 percent of cells maintain viability-Brilacidin was also shown to be non-cytotoxic in the lung cell line. The new lung cell line data reinforce previous testing conducted at the RBL, in VERO cells, where Brilacidin showed a similar robust inhibition, of 75 percent, against SARS-CoV-2 compared to control. Brilacidin has also been shown, in testing at the RBL, to be non-cytotoxic in VERO cells. Additional details on the Brilacidin anti-SARS-CoV-2 testing being conducted at the RBL are planned to be submitted for publication upon completion. Testing results observed to date formed the basis for a federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin's potential as a pan-coronavirus therapeutic, with possible extension into other viruses. The Company is in the process of manufacturing Brilacidin for intravenous dosing and will be seeking FDA guidance for a planned COVID-19 clinical study.

ShowHide Related Items >><<
IPIX Innovation Pharmaceuticals
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.